Correlation Between Cardio Diagnostics and Biodexa Pharmaceticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cardio Diagnostics and Biodexa Pharmaceticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cardio Diagnostics and Biodexa Pharmaceticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cardio Diagnostics Holdings and Biodexa Pharmaceticals, you can compare the effects of market volatilities on Cardio Diagnostics and Biodexa Pharmaceticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cardio Diagnostics with a short position of Biodexa Pharmaceticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cardio Diagnostics and Biodexa Pharmaceticals.

Diversification Opportunities for Cardio Diagnostics and Biodexa Pharmaceticals

0.5
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Cardio and Biodexa is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding Cardio Diagnostics Holdings and Biodexa Pharmaceticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biodexa Pharmaceticals and Cardio Diagnostics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cardio Diagnostics Holdings are associated (or correlated) with Biodexa Pharmaceticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biodexa Pharmaceticals has no effect on the direction of Cardio Diagnostics i.e., Cardio Diagnostics and Biodexa Pharmaceticals go up and down completely randomly.

Pair Corralation between Cardio Diagnostics and Biodexa Pharmaceticals

Given the investment horizon of 90 days Cardio Diagnostics Holdings is expected to generate 1.11 times more return on investment than Biodexa Pharmaceticals. However, Cardio Diagnostics is 1.11 times more volatile than Biodexa Pharmaceticals. It trades about -0.11 of its potential returns per unit of risk. Biodexa Pharmaceticals is currently generating about -0.21 per unit of risk. If you would invest  82.00  in Cardio Diagnostics Holdings on December 29, 2024 and sell it today you would lose (44.00) from holding Cardio Diagnostics Holdings or give up 53.66% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Cardio Diagnostics Holdings  vs.  Biodexa Pharmaceticals

 Performance 
       Timeline  
Cardio Diagnostics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Cardio Diagnostics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Biodexa Pharmaceticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Biodexa Pharmaceticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Cardio Diagnostics and Biodexa Pharmaceticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Cardio Diagnostics and Biodexa Pharmaceticals

The main advantage of trading using opposite Cardio Diagnostics and Biodexa Pharmaceticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cardio Diagnostics position performs unexpectedly, Biodexa Pharmaceticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biodexa Pharmaceticals will offset losses from the drop in Biodexa Pharmaceticals' long position.
The idea behind Cardio Diagnostics Holdings and Biodexa Pharmaceticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Complementary Tools

Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments